HNSBF Stock - Hansa Biopharma AB (publ)
Unlock GoAI Insights for HNSBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $171.32M | $134.09M | $154.53M | $33.88M | $6.10M |
| Gross Profit | $87.76M | $70.95M | $116.05M | $18.45M | $5.10M |
| Gross Margin | 51.2% | 52.9% | 75.1% | 54.5% | 83.7% |
| Operating Income | $-637,878,000 | $-788,496,000 | $-588,588,000 | $-546,978,000 | $-422,807,000 |
| Net Income | $-806,739,000 | $-831,720,000 | $-611,134,000 | $-548,282,000 | $-420,853,000 |
| Net Margin | -470.9% | -620.3% | -395.5% | -1618.4% | -6901.5% |
| EPS | $-12.84 | $-15.83 | $-13.60 | $-12.33 | $-9.98 |
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Visit WebsiteEarnings History & Surprises
HNSBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.18 | $-0.19 | -0.8% | ✗ MISS |
Q3 2025 | Jul 17, 2025 | $-0.17 | $-0.26 | -51.2% | ✗ MISS |
Q2 2025 | Apr 24, 2025 | $-0.27 | $-0.05 | +79.4% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $-0.18 | $-0.37 | -105.8% | ✗ MISS |
Q4 2024 | Oct 17, 2024 | $-0.24 | $-0.16 | +32.9% | ✓ BEAT |
Q3 2024 | Jul 18, 2024 | $-0.26 | $-0.31 | -19.7% | ✗ MISS |
Q2 2024 | Apr 18, 2024 | $-0.32 | $-0.38 | -18.4% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.37 | $-0.23 | +36.3% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $-0.36 | $-0.43 | -19.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.33 | $-0.44 | -34.9% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.28 | $-0.38 | -34.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-0.40 | $-0.31 | +20.4% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-0.17 | $-0.31 | -80.8% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $-0.18 | $-0.37 | -103.5% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | — | $-0.33 | — | — |
Q4 2021 | Dec 31, 2021 | $-0.38 | $-0.40 | -5.6% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | — | $-0.38 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.35 | — | — |
Latest News
Frequently Asked Questions about HNSBF
What is HNSBF's current stock price?
What is the analyst price target for HNSBF?
What sector is Hansa Biopharma AB (publ) in?
What is HNSBF's market cap?
Does HNSBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HNSBF for comparison